#USA #Orlando #OncoPrecision #ONC001 #CD64

Introduction

OncoPrecision Corporation, a pioneer in the field of oncology therapeutics, has announced that its innovative therapy, ONC001, is to be showcased at the 67th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, from December 6-9, 2025. This presentation highlights the company's commitment to advancing cancer treatment through cutting-edge research and development.

About ONC001

ONC001 is a first-in-class antibody-drug conjugate (ADC) specifically designed to target CD64, a receptor found predominantly in chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) subtypes characterized by monocytic differentiation. What sets ONC001 apart is its targeted approach to treating leukemias, particularly those subsets that demonstrate resistance to existing therapies.

The development of ONC001 was made possible by OncoPrecision's unique methodology that combines extensive patient-derived biology and advanced artificial intelligence (AI) systems. This integration allows for the identification of the most vulnerable cellular targets, leading to the successful development of antibodies that have high affinity for neglected targets in cancer treatment.

Significant Research Findings

During the ASH meeting, Dr. Gastón Soria, co-founder and Chief Scientific Officer of OncoPrecision, will delve into compelling preclinical results supporting ONC001. Some of the key findings to be discussed include:

1. Patient-Derived Engagement: The ADC has shown significant engagement with CMML and AML cells sourced from patients, indicating its potential effectiveness in real-world applications.
2. Efficacy Against Resistant Samples: The therapy displayed robust activity even in cellular models resistant to the current standards of care, which is a notable achievement in oncological therapy.
3. In Vivo Effectiveness: Impressive in vivo efficacy data from both heterotopic and orthotopic models will also be revealed, providing insights into the treatment's potential performance across different tumor settings.

The Presentation Details

Dr. Soria's oral presentation, titled "ONC001: A First-in-Class ADC Targeting CD64 for the Treatment of Monocytic Leukemia Developed Through Patient-Guided Target and Payload Selection," is scheduled for December 6, during the session on Molecular Pharmacology and Drug Resistance. This prime slot signifies the importance of ONC001 within discussions on overcoming therapy resistance in AML.

• - Location: OCCC – Valencia Room W415D
• - Session Time: 4:00 PM – 5:30 PM
• - Presentation Time: 5:15 PM – 5:30 PM

The Vision for ONC001

Tarek Zaki, co-founder and CEO of OncoPrecision, emphasized the significance of presenting ONC001 at ASH, stating that it underscores the novel approach their company is taking to tackle blood cancers that have remained difficult to treat due to resistance mechanisms. With the data presented at ASH, OncoPrecision hopes to engage with global partners for potential collaborations aimed at expediting the clinical development of ONC001.

Dr. Soria highlighted that while CD64 has been recognized as a biomarker for monocytic leukemia, no approved treatments have successfully targeted this pathway until now. By employing an ADC modality, OncoPrecision aims to utilize this previously overlooked target for effective therapeutic interventions.

Conclusion

OncoPrecision continues to be at the forefront of cancer therapy innovation with the development of ONC001. The upcoming ASH Annual Meeting presents a pivotal moment for the company to share its advancements and set the stage for further developments in the fight against hematologic malignancies. As the scientific community gathers, the anticipation surrounding ONC001 reflects a shared hope for improved outcomes for patients battling aggressive forms of leukemia.